PT  - JOURNAL ARTICLE
AU  - Baum, Richard P.
AU  - Singh, Aviral
AU  - Schuchardt, Christiane
AU  - Kulkarni, Harshad R.
AU  - Klette, Ingo
AU  - Wiessalla, Stefan
AU  - Osterkamp, Frank
AU  - Reineke, Ulrich
AU  - Smerling, Christiane
TI  - <sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
AID  - 10.2967/jnumed.117.193847
DP  - 2018 May 01
TA  - Journal of Nuclear Medicine
PG  - 809--814
VI  - 59
IP  - 5
4099  - http://jnm.snmjournals.org/content/59/5/809.short
4100  - http://jnm.snmjournals.org/content/59/5/809.full
SO  - J Nucl Med2018 May 01; 59
AB  - Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers, with a very poor prognosis. Eligible patients were offered salvage radiopharmaceutical therapy with the novel NTR1 antagonist 177Lu-3BP-227. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received 177Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities of 5.1–7.5 GBq. Results: Administration of 177Lu-3BP-227 was well tolerated by all patients. The kidneys were identified as the dose-limiting organ. The most severe adverse event was reversible grade 2 anemia. One patient achieved a partial response and experienced significant improvement of symptoms and quality of life. This patient survived 13 mo from diagnosis and 11 mo from the start of 177Lu-3BP-227 therapy. Conclusion: This initial report provides clinical evidence of the feasibility of treatment of ductal pancreatic adenocarcinoma using 177Lu-3BP-227.